Kendall Capital Management Purchases Shares of 5,881 United Therapeutics Corporation $UTHR

Kendall Capital Management purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,881 shares of the biotechnology company’s stock, valued at approximately $3,187,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Torren Management LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management raised its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics during the 4th quarter valued at about $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 442,575 shares of company stock worth $239,326,330 in the last ninety days. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Stock Down 1.5%

Shares of UTHR opened at $513.12 on Friday. The company has a market capitalization of $22.01 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35. The stock’s 50-day moving average price is $533.08 and its 200-day moving average price is $537.36.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the business earned $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on UTHR. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America dropped their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.